Liver transplantation in malignant disease

World J Clin Oncol. 2021 Aug 24;12(8):623-645. doi: 10.5306/wjco.v12.i8.623.

Abstract

Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology. Following the implementation of the Milan criteria, hepatocellular carcinoma (HCC) was the first generally accepted indication for transplantation in patients with cancer. Subsequently, more liberal criteria for HCC have been developed, and research on this topic is still ongoing. The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies. Regarding perihilar cholangiocarcinoma, more and more evidence supports the use of liver transplantation, especially after neoadjuvant therapy. In addition, some data also show a benefit for selected patients with very early stage intrahepatic cholangiocarcinoma. Hepatic epithelioid hemangioendothelioma is a very rare but nonetheless established indication for liver transplantation in primary liver cancer. In contrast, patients with hepatic angiosarcoma are currently not considered to be optimal candidates. In secondary liver tumors, neuroendocrine cancer liver metastases are an accepted but comparability rare indication for liver transplantation. Recently, some evidence has been published supporting the use of liver transplantation even for colorectal liver metastases. This review summarizes the current evidence for liver transplantation for primary and secondary liver cancer.

Keywords: Cholangiocellular carcinoma; Colorectal cancer liver metastases; Hepatic epithelioid hemangioendothelioma; Hepatocellular carcinoma; Liver transplantation; Neuroendocrine cancer liver metastases; Undifferentiated embryonal sarcoma of the liver.

Publication types

  • Review